An Open-label Phase II Study of Lorvotuzumab Mertansine

NCT02420873 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: Lorvotuzumab Mertansine (IMGN901)

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]